Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Faratian, Dana ^a   Sims, Andrew H ^a   Mullen, Peter ^a   Kay, Charlene ^a   Um, InHwa ^a   Langdon, Simon P ^a   Harrison, David J ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SPROUTY 2 PROTEIN; SPROUTY PROTEIN; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; SIGNAL PEPTIDE; SPRY2 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER MORTALITY; CONTROLLED STUDY; DRUG SENSITIVITY; GENE; GENE EXPRESSION; GENETIC ASSOCIATION; HER2 GENE; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEGATIVE FEEDBACK; PROGNOSIS; PROTEIN EXPRESSION; SPROUTY 2 GENE; TUMOR SUPPRESSOR GENE; AGED; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECT; FEEDBACK SYSTEM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME;

EID: 80052332155     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023772     Document Type: Article

References (38)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672.
2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684.
3. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395-402.
4. Scaltriti M, Rojo F, Ocana A, Anido J, Guzman M, et al. (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99: 628-638.
5. Valabrega G, Montemurro F, Aglietta M, (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18: 977-984.
6. Egan JE, Hall AB, Yatsulat BA, Bar-Sagi D, (2002) The bimodal regulation of epidermal growth factor signaling by human Sprouty proteins. Proceedings of the National Academy of Sciences of the United States of America 99: 6041-6046.
7. Hacohen N, Sutherland D, Krasnow MA, Kramer S, Hiromi Y, et al. (1998) Sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways. Cell 92: 253-263.
8. Hall AB, Jura N, DaSilva J, Jang YJ, Gong D, et al. (2003) hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl. Current Biology 13: 308-314.
9. Leeksma OC, Van Achterberg TAE, Tsumura Y, Toshima J, Eldering E, et al. (2002) Human sprouty 4, a new ras antagonist on 5q31, interacts with the dual specificity kinase TESK1. European Journal of Biochemistry 269: 2546-2556.
10. Mason JM, Morrison DJ, Bassit B, Licht JD, Gross I, et al. (2004) Tyrosine Phosphorylation of Sprouty Proteins Regulates Their Ability to Inhibit Growth Factor Signaling: A Dual Feedback Loop. Molecular Biology of the Cell 15: 2176-2188.
11. Sasaki A, Taketomi T, Wakioka T, Kato R, Yoshimura A, et al. (2001) Identification of a Dominant Negative Mutant of Sprouty that Potentiates Fibroblast Growth Factor-but Not Epidermal Growth Factor-induced ERK Activation. Journal of Biological Chemistry 276: 36804-36808.
12. Wong ESM, Fong CW, Lim J, Yusoff P, Low BC, et al. (2002) Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling. EMBO Journal 21: 4796-4808.
13. Lo TL, Yusoff P, Fong CW, Guo K, McCaw BJ, et al. (2004) The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer. Cancer Res 64: 6127-6136.
14. McKie AB, Douglas DA, Olijslagers S, Graham J, Omar MM, et al. (2005) Epigenetic inactivation of the human sprouty2 (hSPRY2) homologue in prostate cancer. Oncogene 24: 2166-2174.
15. Wang J, Thompson B, Ren C, Ittmann M, Kwabi-Addo B, (2006) Sprouty4, a suppressor of tumor cell motility, is down regulated by DNA methylation in human prostate cancer. Prostate 66: 613-624.
16. Fritzsche S, Kenzelmann M, Hoffmann MJ, Muller M, Engers R, et al. (2006) Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma. Endocr Relat Cancer 13: 839-849.
17. Sims AH, Smethurst GJ, Hey Y, Okoniewski MJ, Pepper SD, et al. (2008) The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets- improving meta-analysis and prediction of prognosis. BMC Med Genomics 1: 42.
18. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais NL, et al. (2007) High-resolution aCGH and expression profiling identifies a novel genomic subtype of ER negative breast cancer. Genome Biol 8: R215.
19. Pawitan Y, Bjohle J, Amler L, Borg AL, Egyhazi S, et al. (2005) Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res 7: R953-R964.
20. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
21. Desmedt C, Giobbie-Hurder A, Neven P, Paridaens R, Christiaens MR, et al. (2009) The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics 2: 40.
22. Ivshina AV, George J, Senko O, Mow B, Putti TC, et al. (2006) Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer Res 66: 10292-10301.
23. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, et al. (2005) Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365: 671-679.
24. Chen DT, Nasir A, Culhane A, Venkataramu C, Fulp W, et al. (2010) Proliferative genes dominate malignancy-risk gene signature in histologically-normal breast tissue. Breast Cancer Res Treat 119: 335-346.
25. Lu X, Lu X, Wang ZC, Iglehart JD, Zhang X, et al. (2008) Predicting features of breast cancer with gene expression patterns. Breast Cancer Res Treat 108: 191-201.
26. Fong CW, Chua MS, McKie AB, Ling SH, Mason V, et al. (2006) Sprouty 2, an inhibitor of mitogen-activated protein kinase signaling, is down-regulated in hepatocellular carcinoma. Cancer Res 66: 2048-2058.
27. Wong ES, Lim J, Low BC, Chen Q, Guy GR, (2001) Evidence for direct interaction between Sprouty and Cbl. J Biol Chem 276: 5866-5875.
28. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, et al. (2009) Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 69: 6713-6720.
29. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847.
30. Camp RL, Chung GG, Rimm DL, (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 8: 1323-1327.
31. Giltnane JM, Molinaro A, Cheng H, Robinson A, Turbin D, et al. (2008) Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med 132: 1635-1647.
32. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, et al. (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97: 1180-1184.
33. Camp RL, Dolled-Filhart M, Rimm DL, (2004) X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 10: 7252-7259.
34. Altman DG, Lausen B, Sauerbrei W, Schumacher M, (1994) Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86: 829-835.
35. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
36. Edwin F, Singh R, Endersby R, Baker SJ, Patel TB, (2006) The tumor suppressor PTEN is necessary for human Sprouty 2-mediated inhibition of cell proliferation. J Biol Chem 281: 4816-4822.
37. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
38. Kola I, Landis J, (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715.